Corporate Presentation January 2016
Presentation

ASH 2015 Investor and Analyst Event
Presentation

ASH 2014 Investor and Analyst Event
Presentation

 

Asterias Stock Tax Guidance
Download here

 
Corporate Profile
Geron is a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
Recent NewsMore >>
DateTitle 
01/14/16Geron Announces Initiation of Janssen Phase 2/3 Clinical Trial of Imetelstat in Myelodysplastic SyndromesPrinter Friendly Version
11/30/15Geron Announces December Conference Presentation WebcastsPrinter Friendly Version
11/10/15Geron to Present at the Stifel Healthcare ConferencePrinter Friendly Version
Upcoming EventsMore >>
To be announced.
Stock Information
GERN (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$2.86
Change (%) Stock is Down 0.09 (3.05%)
Volume2,107,075
Data as of 02/05/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
  
Contact Information

Anna Krassowska, Ph.D.
Tel: 650-473-7700
E-mail: investor@geron.com or media@geron.com



RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | Financial Tear Sheet Financial Tear Sheet
Close
Form content here please :)